[Federal Register Volume 66, Number 64 (Tuesday, April 3, 2001)]
[Notices]
[Pages 17722-17723]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-8088]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Identification of TRP-2 
as a New Human Tumor Antigen Recognized by Cytotoxic T Lymphocytes

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 
404.7(a)(1)(i), that the National Institutes of Health. Department of 
Health and Human Services, is contemplating the grant of an exclusive 
license to practice the inventions embodied in U.S. Patent Applications 
S/N 08/725,736, filed on October 4, 1996, and now U.S. Patent 5,831,016 
which issued on November 3, 1998; S/N 09/161,877 (DIV of 08/725,736), 
filed on September 28, 1998, and now U.S. Patent 6,132,980 which issued 
on October 17, 2000; S/N 09/162,368 (DIV of 08/725,736), filed on 
September 28, 1998, and now U.S. Patent 6,083,703 which issued on July 
4, 2000; and S/N 09/651,210 (DIV of 08/725,736), filed on August 30, 
2000, all entitled ``Identification of TRP-2 as a New

[[Page 17723]]

Human Tumor Antigen Recognized by Cytotoxic T Lymphocytes'; and PCT 
Patent Application PCT/US97/02186 (based upon U.S. Patent Applications 
S/N 08/599,602 and 08/725,736) filed on February 6, 1997, entitled 
``Human Cancer Antigen of Tyrosinase-Related Protein 1 and 2 and Genes 
Encoding Same'', to ImClone Systems Incorporated of New York, New York. 
The patent rights in these inventions have been assigned to the United 
States of America.
    The prospective exclusive license territory will be worldwide and 
the field of use may be limited to protein vaccines consisting of the 
full-length TRP-2 protein or the lumenal portion thereof. Fragments or 
peptides of TRP-2 can be used together with gp75 and/or Tyrosinase or 
fragments or peptides thereof for use as human anti-melanoma 
therapeutics but only when used in multimeric form, that is when 
multiple different epitopes are expressed contiguously in the said 
vaccine. Specifically excluded from the field of use are TRP-2 
fragments or peptides (other than the afore-mentioned lumenal portion) 
used in a monomeric form, to be used either alone or in combination 
with other peptides, proteins, or other recombinant vector, DNA or RNA 
vaccines or vaccination protocols. Also excluded are the use of nucleic 
acid sequences encoding the TRP-2 antigen in any form including those 
used in any viral, bacterial, DNA and RNA vaccine or vaccination 
protocol.

DATES: Only written comments and/or license applications which are 
received by the National Institutes of Health on or before June 4, 2001 
will be considered.

ADDRESSES: Requests for copies of the patent/patent applications, 
inquiries, comments and other materials relating to the contemplated 
exclusive license should be directed to: Elaine White, M.B.A., 
Technology Licensing Specialist, Office of Technology Transfer, 
National Institutes of Health, 6011 Executive Boulevard, Suite 325, 
Rockville, MD. 20852-3804. Telephone: (301) 496-7056, X282; Facsimile 
(301) 402-0220; E-mail [email protected].

SUPPLEMENTARY INFORMATION: The prospective exclusive license will be 
royalty-bearing and will comply with the terms and conditions of 35 
U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be 
granted unless within sixty (60) days from the date of this published 
notice, the NIH receives written evidence and argument that establish 
that the grant of the license would not be consistent with the 
requirements of 35 U.S.C. 209 and 37 CFR 404.7.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: March 23, 2001.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health
[FR Doc. 01-8088 Filed 4-2-01; 8:45 am]
BILLING CODE 4140-01-P